BG64584B1 - Фармацевтични състави, съдържащи вориконазол - Google Patents

Фармацевтични състави, съдържащи вориконазол Download PDF

Info

Publication number
BG64584B1
BG64584B1 BG103882A BG10388299A BG64584B1 BG 64584 B1 BG64584 B1 BG 64584B1 BG 103882 A BG103882 A BG 103882A BG 10388299 A BG10388299 A BG 10388299A BG 64584 B1 BG64584 B1 BG 64584B1
Authority
BG
Bulgaria
Prior art keywords
voriconazole
formula
cyclodextrin
pharmaceutically acceptable
composition according
Prior art date
Application number
BG103882A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103882A (en
Inventor
Valerie Harding
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64584(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103882A publication Critical patent/BG103882A/xx
Publication of BG64584B1 publication Critical patent/BG64584B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
BG103882A 1997-06-21 1999-11-15 Фармацевтични състави, съдържащи вориконазол BG64584B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations
PCT/EP1998/003477 WO1998058677A1 (fr) 1997-06-21 1998-06-02 Formulations pharmaceutiques contenant du voriconazole

Publications (2)

Publication Number Publication Date
BG103882A BG103882A (en) 2000-07-31
BG64584B1 true BG64584B1 (bg) 2005-08-31

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103882A BG64584B1 (bg) 1997-06-21 1999-11-15 Фармацевтични състави, съдържащи вориконазол

Country Status (48)

Country Link
US (1) US6632803B1 (fr)
EP (1) EP1001813B8 (fr)
JP (2) JP2000513029A (fr)
KR (1) KR100372988B1 (fr)
CN (1) CN1125653C (fr)
AP (1) AP912A (fr)
AR (1) AR015900A1 (fr)
AT (1) ATE238812T1 (fr)
AU (1) AU724799B2 (fr)
BG (1) BG64584B1 (fr)
BR (1) BRPI9809468B8 (fr)
CA (1) CA2295035C (fr)
CO (1) CO4940450A1 (fr)
CZ (1) CZ289570B6 (fr)
DE (1) DE69814091T2 (fr)
DK (1) DK1001813T3 (fr)
DZ (1) DZ2523A1 (fr)
EA (1) EA001924B1 (fr)
EG (1) EG23910A (fr)
ES (1) ES2195355T3 (fr)
GB (1) GB9713149D0 (fr)
HK (1) HK1027966A1 (fr)
HR (1) HRP980341B1 (fr)
HU (1) HU228338B1 (fr)
ID (1) ID22939A (fr)
IL (1) IL132918A (fr)
IS (1) IS2004B (fr)
MA (1) MA26508A1 (fr)
ME (1) ME00907B (fr)
MY (1) MY118151A (fr)
NO (1) NO313125B1 (fr)
NZ (1) NZ501066A (fr)
OA (1) OA11232A (fr)
PA (1) PA8453201A1 (fr)
PE (1) PE84899A1 (fr)
PL (1) PL191295B1 (fr)
PT (1) PT1001813E (fr)
RS (1) RS49633B (fr)
SA (1) SA98190159B1 (fr)
SI (1) SI1001813T1 (fr)
SK (1) SK282946B6 (fr)
TN (1) TNSN98090A1 (fr)
TR (1) TR199903191T2 (fr)
TW (1) TW406023B (fr)
UA (1) UA57083C2 (fr)
UY (1) UY25055A1 (fr)
WO (1) WO1998058677A1 (fr)
ZA (1) ZA985364B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US7115587B2 (en) * 2002-08-20 2006-10-03 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
MXPA06006291A (es) * 2003-12-08 2006-08-23 Univ Arizona Composiciones anti-cancer sinergisticas.
CA2572223C (fr) 2004-06-25 2014-08-12 The Johns Hopkins University Inhibiteurs d'angiogenese
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
EP2018866A1 (fr) * 2007-07-27 2009-01-28 Sandoz AG Compositions pharmaceutiques contenant du voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (fr) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Traitement d’infection fongique pulmonaire avec du voriconazole et par inhalation
US20110105448A1 (en) * 2008-06-06 2011-05-05 Glenmark Pharmaceuticals Limited Stable Topical Formulation Comprising Voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药***
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
WO2011020605A1 (fr) 2009-08-19 2011-02-24 Ratiopharm Gmbh Procédé de production de co-évaporats et de complexes comprenant un voriconazole et une cyclodextrine
WO2011064558A2 (fr) 2009-11-30 2011-06-03 Cipla Limited Composition pharmaceutique
BR112012033077B8 (pt) 2010-06-29 2023-04-25 Merck Sharp & Dohme Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
EP2409699B1 (fr) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Compositions stables de voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
PL2720723T3 (pl) 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
EP2561863A1 (fr) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Compositions pharmaceutiques comportant du voriconazole
WO2013103924A2 (fr) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Glutathione réduite encapsulée dans un liposome pour le traitement du cancer, y compris en combinaison avec d'autres compositions pharmaceutiques
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
EP2662094B1 (fr) 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Procédés de complexation cyclodextrine pour formuler des inhibiteurs du protéasome de peptide
MX2014013714A (es) 2012-05-11 2015-08-10 Cipla Ltd Composicion farmaceutica.
CA2897330C (fr) 2013-01-11 2021-01-26 Xellia Pharmaceuticals Aps Complexes d'inclusion de voriconazole
US20140275122A1 (en) 2013-03-14 2014-09-18 Fresenius Kabi Usa, Llc Voriconazole Formulations
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
EP3541364A1 (fr) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Nouvelles formulations de composés de la famille des bêta-lactamines substitués par une amidine, à base de cyclodextrines modifiées et d'agents acidifiants, leur préparation et leur utilisation en tant que compositions pharmaceutiques antimicrobiennes
US11040958B2 (en) 2017-02-17 2021-06-22 Wuhan Ll Science And Technology Development Co., Ltd. Triazole antimicrobial derivative, pharmaceutical composition and use thereof
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440372A1 (fr) * 1990-02-02 1991-08-07 Pfizer Limited Triazole comme agents antifongiques
WO1991011172A1 (fr) * 1990-01-23 1991-08-08 The University Of Kansas Derives de cyclodextrines presentant une solubilite aqueuse amelioree et utilisation de ceux-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (fr) * 1990-01-23 1991-08-08 The University Of Kansas Derives de cyclodextrines presentant une solubilite aqueuse amelioree et utilisation de ceux-ci
EP0440372A1 (fr) * 1990-02-02 1991-08-07 Pfizer Limited Triazole comme agents antifongiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода

Also Published As

Publication number Publication date
DE69814091T2 (de) 2004-01-22
SA98190159B1 (ar) 2005-12-21
DZ2523A1 (fr) 2003-02-01
BRPI9809468B8 (pt) 2022-01-18
HK1027966A1 (en) 2001-02-02
MA26508A1 (fr) 2004-12-20
BR9809468B1 (pt) 2013-11-12
ATE238812T1 (de) 2003-05-15
CA2295035A1 (fr) 1998-12-30
CA2295035C (fr) 2005-04-19
CN1125653C (zh) 2003-10-29
AR015900A1 (es) 2001-05-30
EP1001813B1 (fr) 2003-05-02
CO4940450A1 (es) 2000-07-24
NO995565L (no) 1999-11-30
PL337692A1 (en) 2000-08-28
US6632803B1 (en) 2003-10-14
ME00907B (me) 2007-08-03
EA199900937A1 (ru) 2000-08-28
CZ409699A3 (cs) 2000-02-16
RS49633B (sr) 2007-08-03
PE84899A1 (es) 1999-09-17
DK1001813T3 (da) 2003-07-28
SI1001813T1 (en) 2004-02-29
OA11232A (en) 2003-05-26
WO1998058677A1 (fr) 1998-12-30
IS5248A (is) 1999-11-15
NO995565D0 (no) 1999-11-12
UA57083C2 (uk) 2003-06-16
SK159399A3 (en) 2000-06-12
TR199903191T2 (xx) 2000-09-21
CZ289570B6 (cs) 2002-02-13
PA8453201A1 (es) 2000-05-24
AP912A (en) 2001-12-08
GB9713149D0 (en) 1997-08-27
UY25055A1 (es) 2000-12-29
HU228338B1 (en) 2013-03-28
TNSN98090A1 (fr) 2005-03-15
BG103882A (en) 2000-07-31
NO313125B1 (no) 2002-08-19
ES2195355T3 (es) 2003-12-01
ZA985364B (en) 1999-12-20
KR20010014006A (ko) 2001-02-26
NZ501066A (en) 2001-01-26
EG23910A (en) 2007-12-30
HUP0003323A3 (en) 2002-01-28
SK282946B6 (sk) 2003-01-09
IL132918A (en) 2001-09-13
KR100372988B1 (ko) 2003-02-25
IL132918A0 (en) 2001-03-19
IS2004B (is) 2005-04-15
YU68199A (sh) 2002-06-19
JP2000513029A (ja) 2000-10-03
AU8110498A (en) 1999-01-04
JP2002332234A (ja) 2002-11-22
EP1001813A1 (fr) 2000-05-24
HRP980341B1 (en) 2001-12-31
MY118151A (en) 2004-09-30
TW406023B (en) 2000-09-21
ID22939A (id) 1999-12-16
BR9809468A (pt) 2000-06-20
EA001924B1 (ru) 2001-10-22
AP9801268A0 (en) 1998-06-30
PT1001813E (pt) 2003-07-31
EP1001813B8 (fr) 2014-02-12
JP5089004B2 (ja) 2012-12-05
PL191295B1 (pl) 2006-04-28
HRP980341A2 (en) 1999-02-28
AU724799B2 (en) 2000-09-28
HUP0003323A2 (hu) 2001-06-28
DE69814091D1 (de) 2003-06-05
CN1261287A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
BG64584B1 (bg) Фармацевтични състави, съдържащи вориконазол
AU2003234285B2 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
JP4202273B2 (ja) フマギロール誘導体又はその塩の包接化合物、及び該包接化合物を含む医薬組成物
AU2003205930B2 (en) Pharmaceutical composition
KR20040005995A (ko) 주사용 실로스타졸 수성 제제
CA2486571C (fr) Composition medicinale
MXPA99012075A (en) Pharmaceutical formulations containing voriconazole
JPH02172913A (ja) ポリプレニル系化合物含有注射剤